Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
The sad sob story goes on and now reinforced by a respected body, BIVDA.
The real detail of how and who made the decision to stop supporting the UK diagnostic industry will eventually come out, but I think it stems from the all the negative press around the Test n Trace spend of £38bn for little result! Oh if only a fraction of that went to UK diagnostics! Even if the UK could not provide the volume of LFT's in the early stages they should still have been supported as a back up and to future proof the UK (even though nobody expected at the time that we would be overwhelmed by Omicron so quickly, but that is what future proofing for!!).
"But the continued reticence to even approve tests for private sale in the UK, let alone public provision, is pure market distortion."
I agree that the delay (CTDA now over 120 days!) can be construed as very suspicious, but again is it deliberate or just incompetence/lack of resources or even clarification of the original application!?
The other explanation is a premature change of strategy (away from mass testing/Operation Moonshot, departure of Cummings) in order to supposedly save money (thinking that last summer was the beginning of the end of the pandemic, hence no need for a big testing requirement) combined with incompetence and unwilling to continue to support the UK diagnostic industry for now and the future (save money again) Spending £38bn on Test n Trace didn't help negative attitude to testing in HMG in mid 2020! Overall a premature move away from testing (hence cancelling ODX contract, etc). THEN Omicron arrives and they are caught with their pants down. It is similar in the US, only now are they realising the need for testing (many US test companies descaled last year!).
Of course, there is always the conspiracy theory that they actually want fewer and sub standard tests to give the pretence that they are doing something, while really letting Omicron rip to achieve herd immunity sooner! Not convinced that was a deliberate strategy, but they may have just slid into it (unwittingly) and now accept it, rather than admit the current approved tests are not the best, but they are available (mostly and can be scaled up).
Does passing uk desk top review (CTDA) plus CE for home use in Europe (received) allow us to sell for home use in uk? Or does it still have to get EUA for home use in uk?
Maybe the CTDA application/process was for prof use only?
Its all a matter of saving face! HMG do not want to admit that Innova are crap and would rather the virus run riot! It is not about saving lives it is about saving face and their jobs!
Also Innova were one of a few that could provide the volume over a year ago, however that does not excuse HMG from leaving the UK diagnostics industry in the lurch last summer. They could have won plaudits and saved red wall seats if they had followed through with support for UK diagnostics, what an opportunity missed! Maybe late now, but is it too late, I think not!
No price sensitive information can be released at the AGM that has not previously been RNS'd!
Most investors want to see revenue/profit figures and projections so that they can make a rational/logical calculation of value/sp, based on say a p/e of 10-30! However there are many embryo innovative companies with disruptive technology (like Avacta) that have little to no earnings (and zero profit) yet still have values in the billions, purely because of perceived potential. Take Tesla , p/e 345, 10 times higher than say Ford, p/e 28! Some silicon valley companies have a p/e of infinity.
However these amazing valuations tend to be US based, I don't expect crazy p/e's on Aim in the UK,. but Fevertree on p/e 70 might be closer to likely!
Also any takeover has to be supported by the shareholders (II's and PI's), so (IMO) a low bid is unlikely to be successful unless it was a knockout bid of several billion!
The NHS LFT's are Chinese repackaged as supplied by MHRA/NHS, mainly Innova and Optigene!
I believe (hopefully not naively) that real news is imminent, TT to Abingdon, Desk top review from MHRA, HUA, and Ava6000 interim results (all of which are significant sp movers!). Because all of these are just about there (?) then there is absolutely no point in AS putting out a general update or putting on another vague video, IN FACT I think it would be detrimental to the sp, and our new Nomad will be advising accordingly.
SO no update until real facts can be clearly communicated.
IMO not long to wait!
BB2,
You are absolutely right and specific and they are not, they have been very deliberately non specific and that is quite telling! Guff about no more quarterly updates and only specific ones is just ridiculous, as any major news would be rns’d outside of the quarterly cycle anyway!
They are out of their depth for a registered fuse company and the controls n practices required.......albeit with a good product and a great potential!
The BoD, the II’s and the pi’s would never agree to a buyout anywhere near current mcap, so just wont happen! A hostile bid would require a majority of shareholders to agree, ii’s hold more than 50% and would be wanting way more than current mcap, more like £5++! A few desperate pi’s might agree to £2+, but not enough to carry the day! So any successful bid would have to be mega! Imho
I agree the therapeutics side is totally undervalued. The sp only really reflects the lack of news on the diagnostics.....driven by Aim traders after a quick buck........thats AIM for you though! If this had US exposure then the sp would £5+ on clinical trials alone!
Marik/roundhowe,
Surely AS cannot keep totally silent on the trial progress until December. I would have thought an interim statement to the effect of "The trial is progressing satisfactorily with no major concerns" would be put at the half way stage?.......your thoughts? Maybe scientists/medics never will make pre-emoptive general statements until the facts/data have been fully analysed!?